Advancing pharmacy practice through specialized board certification in biologics and biosimilars: Implications and Opportunities

Purpose: The emergence of specialized board certifications, such as the Board-Certified Biologics and Biosimilars Specialist (BCBBS), represents a transformative opportunity in pharmacy practice. This paper explores the impact of such certifications on patient care and the evolving pharmaceutical landscape. Summary: With increasing use of biologics and biosimilars, pharmacists equipped with certification are positioned to enhance patient outcomes, implement safer protocols, and close knowledge gaps in healthcare delivery. The introduction of BCBBS by the Accreditation Council for Medical Affairs (ACMA) offers specialized pharmacists training to manage complex therapies. The article reviews the broader implications of certification including improved interprofessional collaboration, enhanced pharmacist authority in care teams, and better clinical outcomes. Key challenges, such as payer restrictions, patent law barriers, and knowledge deficits, are also examined. Conclusion: Board certification in biologics and biosimilars is a valuable advancement in pharmaceutical education and healthcare delivery. Pharmacists with specialized training can serve as leaders in biosimilar implementation, cost containment, and equitable patient care.